We’re excited to share some highlights from our recent Neuroscience Investor Event with Nevrargenics Ltd. The event, held on April 9th, 2024, was a fantastic gathering of business professionals, investors, and healthcare experts passionate about advancing neurodegenerative disease research and treatment.

The evening commenced with an excellent overview of neuroscience challenges and current medical status, given by world authority Professor Susan Duty of King’s College, London and followed by a great presentation from the Nevrargenics core team, including Professor Andy Whiting, Dimitri Dimitriou, James Bromhead and Anthony Lockett. Their insights into the innovative RAR-M drug development targeting Alzheimer’s and Parkinson’s diseases were both compelling and detailed, giving attendees a clear picture of the cutting-edge approach driving the company’s progress in this field. One of the most impressive aspects of the event was the level of engagement and interest from attendees, with a vibrant Q&A session.

Nevrargenics is targeting a $5m equity fundraise which will trigger a potential $7.5m grant offered by the Funding Partnership, linked to the UN. Stakeholderz is pleased to be coordinating this fundraising in close conjunction with the company. We would like to thank everyone who attended the event and played a part in making it a success.